SPOTLIGHT -
March 17th 2023
A look back on what happened in optometry during the week of March 10-March 16.
March 14th 2023
Research shows how life stressors—such as obesity—reprogram immune system cells and make them destructive to the eye as it ages.
March 3rd 2023
A look back on what's happened in optometry during the week of February 25-March 2.
February 24th 2023
A look back on what's happened in optometry during the week of February 18-February 23.
February 16th 2023
The eye care community is moving toward a more disruption-resistant system of care, from wearable tech to VEGF-eluting implants.
Poll results: How comfortable are you with including biosimilars in your treatment plans?
See the results from our recent poll!
Study shows positive improvement on combined treatment for wet AMD
OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD
Poll: How comfortable are you with including biosimilars in your treatment plans?
Vote in our most recent poll!
Introduction to biosimilars for AMD
Advances in drug creation would reduce cost burden of treatment for patients.
Poll results: Have you referred a patient with AMD for a low vision evaluation?
ONYX trial results: Combo therapy gives no added benefit when treating nAMD
The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.
FDA approves ML6710i photodynamic laser for use with VISUDYNE
Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.
Poll: Have you referred a patient with AMD for a low vision evaluation?
Kicking off AMD Awareness Month, give us your thoughts!
Contact lenses can help patients with low vision
Benefits include eliminating eyeglass problems and boosting patient confidence.
This week in optometry: January 1-January 5
A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.
Managing low vision in an aging population
As Baby Boomers enter the at-risk age group for vision loss, optometrists must be ready to act.
Long-term metformin use not associated with AMD risk
A multicenter US study revealed that the long-term use of metformin to treat diabetes and lifestyle changes in patients with diabetes were not associated with the risk of age-related macular degeneration (AMD).
A look back: Optometry in 2022
As 2022 comes to a close, check out some of the hottest and most-liked stories from the year!
Geographic atrophy: What to know and why
Look out for at-risk patients and prepare to establish treatment protocols.
Apellis aims to submit 24-month Phase 3 data to FDA for pegcetacoplan NDA
The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.
Seeing a clear path to the solution: solving the global vision crisis
World Sight Day is upon us and RestoringVision has issued a lofty but doable goal: help solve the global vision crisis.
Report shows increase of visual decline in AMD patients during COVID-19 lockdown
Treatment suspension has negative impact on visual function.
Supplements slow AMD progression, study data confirm
AREDS2 formula doesn’t contain beta carotene, reducing the risk of lung cancer.
Heru expands AMD portfolio with new launch
With the launch of dark adaptation, Heru is now the only platform on the AMD market to include contrast sensitivity and dark adaptation exams.
Apellis releases 24-month results of phase 3 studies for GA treatment
Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.
FDA approves biosimilar product ranibizumab-eqrn for retinal diseases
Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.
Study: Skipping breakfast linked to decreased risk of AMD
Korean investigators have found intermittent fasting may actually lead to a lower risk of developing AMD in the elderly population.
Apellis receives FDA acceptance, priority review of NDA for GA treatment
If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.
Imaging technology helps in scanning for retinal diseases
Advancements enable better diagnosis, treatment of patients.
New 2-year data supports faricimab-svoa for treatment of wet AMD
Presented during the 2022 ASRS meeting, results find that over 60% of participants could be treated every 4 months at 2 years—an increase from 45% at year 1.
Study confirms supplements slow AMD progression
A decade after the conclusion of the NIH-funded AREDS2 study, researchers found that the AREDS2 formula also reduces the risk of lung cancer.
LIGHTSITE III trial data shows vision improvement in intermediate dry AMD
Trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.
AMD: What to look for and how to deal with It
Elena Biffi, OD, MSc, FAAO, dives into AMD, a multifactorial disease that requires a multimodal diagnostic imaging approach.
Digital health care in optometry
Embracing this new model of care can allow optometric practices to flourish—and may enable earlier detection of conversion from intermediate dry to wet AMD.
Advances in the management of dry AMD
Early diagnosis and intervention are crucial when managing this patient base.